PRELUDE CAPITAL MANAGEMENT, LLC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 114 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.9%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$100,000
-6.5%
14,800
+15.6%
0.00%0.0%
Q4 2021$107,000
+37.2%
12,800
+12.3%
0.00%
+50.0%
Q2 2021$78,000
+3800.0%
11,400
+5600.0%
0.00%
Q3 2020$2,000
-94.7%
200
-95.3%
0.00%
-100.0%
Q4 2019$38,000
+81.0%
4,300
+30.6%
0.00%0.0%
Q3 2018$21,000
+16.7%
3,293
+43.2%
0.00%0.0%
Q2 2018$18,0002,3000.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
TRV GP II, LLC 572,829$1,340,000100.00%
TRV GP III, LLC 1,148,780$2,688,0001.17%
COWEN AND COMPANY, LLC 3,647,430$8,535,0000.82%
Octagon Capital Advisors LP 1,400,000$3,276,0000.56%
Deep Track Capital, LP 4,259,653$9,968,0000.46%
PFM Health Sciences, LP 4,094,488$9,581,0000.35%
RTW INVESTMENTS, LP 5,106,341$11,949,0000.28%
Omega Fund Management, LLC 275,513$645,0000.24%
Monarch Partners Asset Management LLC 228,370$534,0000.16%
Orbimed Advisors 2,928,900$6,854,0000.13%
View complete list of JOUNCE THERAPEUTICS INC shareholders